After two intramuscular injections of lanreotide SR at a dose of 30 mg every 10 days, the alpha-fetoprotein (AFP), an important tumour marker for HCC, levels were drastically reduced and when lanreotide therapy was continued, given the good tolerance to the treatment, a slight decrease of tumour size with pronounced signs of necrotic changes were also registered[207]. The gene discussed is AFP; the disease is hepatocellular carcinoma.